Perspective Therapeutics Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
CATX American 3841 https://isoray.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Perspective Therapeutics Inc

Perspective Therapeutics to Participate at Upcoming April Investor Conferences - Apr 8th, 2024 12:00 pm
Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results - Mar 30th, 2024 9:31 am
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results - Mar 28th, 2024 11:30 am
Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal - Mar 19th, 2024 2:39 pm
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma - Mar 18th, 2024 12:00 pm
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 - Mar 11th, 2024 12:00 pm
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility - Mar 5th, 2024 1:00 pm
Perspective Therapeutics Announces $87.4 Million Private Placement - Mar 4th, 2024 2:45 pm
Perspective Therapeutics to Participate at Upcoming Investor Conferences - Feb 26th, 2024 1:00 pm
These Drug Companies Are Going Nuclear to Fight Cancer - Feb 20th, 2024 11:30 am
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth - Feb 13th, 2024 3:00 pm
Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference - Feb 12th, 2024 1:00 pm
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline - Feb 8th, 2024 3:00 pm
Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform - Feb 1st, 2024 1:00 pm
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year? - Jan 30th, 2024 2:40 pm
Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement - Jan 22nd, 2024 9:05 pm
Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement - Jan 18th, 2024 12:00 pm
Perspective Therapeutics Announces Proposed Public Offering - Jan 17th, 2024 9:05 pm
Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01 - Jan 17th, 2024 1:00 pm
Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability - Jan 9th, 2024 1:00 pm